0
likes
0
comments
daily view 0
monthly view 0
Live Analytics
Comments 0
Why Cancer Immunotherapy Fails on Cold Tumors and How to Fix It Analytics Table
Income Estimates for Why Cancer Immunotherapy Fails on Cold Tumors and How to Fix It
Based on this YouTube video's total view count of 219 views and industry-standard rates, the estimated total earning is $0 - $0 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.
About Why Cancer Immunotherapy Fails on Cold Tumors and How to Fix It
Explore Why Cancer Immunotherapy Fails on Cold Tumors and How to Fix It with 219 views, 0 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.
Why Cancer Immunotherapy Fails on Cold Tumors and How to Fix It Cancer immunotherapy depends on your immune system finding the target, yet most solid tumors stay invisible. In this episode, George Sens, CEO of LurexBio, explains how their non genetic platform aims to light up immune cold tumors so existing therapies can engage. Host Jonathan W. Buckley also explores what happens when an enterprise software operator steps in to build a preclinical biotech company from the ground up. What you will learn in this conversation: • What immune cold tumors are and why 90 to 95 percent of MSS colorectal cancers evade detection • The difference between immune evasion and immune exclusion in solid tumors • Why LurexBio takes a non genetic approach instead of editing tumor DNA • How biotech startups differ from software with no MVP, no recurring revenue, and preclinical proof first • The fundraising math behind $3.5M to $5M seed rounds and $25M to $75M Series A rounds • How 27 provisional patent filings on delivery and cell membrane attachment create an IP moat 00:00 - Intro and the Immune Cold Tumor Problem 01:53 - Making Solid Tumors Visible to the Immune System 04:25 - James Clark and the Founding Story of LurexBio 06:40 - Building Governance and Biotech Infrastructure 08:30 - Why Biotech Differs From Software Startups 10:35 - Upstream Visibility, Evasion, and Exclusion 12:15 - Non Genetic Approaches and the CSI Effect 13:26 - Biotech Seed and Series A Fundraising Math 16:00 - Boston Research and Strategic Lab Partnerships 17:10 - Process Patents and Building an IP Moat 19:00 - Closing Thoughts and Podcast Links CONNECT WITH GEORGE SENS LinkedIn: https://www.linkedin.com/in/georgesens/ LurexBio: https://lurexbio.com HOST AND SHOW LINKS Jonathan W. Buckley: https://www.jonathanwbuckley.com/ The Artesian Network: https://www.artesiannetwork.com/ Spotify: https://open.spotify.com/show/6Jweh5o7ohcVthBb4wZ2vp Apple Podcasts: https://podcasts.apple.com/podcast/id1896267895 Every Episode: https://www.WeBuiltItBecauseWeHadTo.com #CancerImmunotherapy #Immunotherapy #BiotechStartup
About YouTube Real-Time View Count
With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.
Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.
Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.
Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.
Embed Widget
Parameters:
fullscreen=true- Fullscreen countergraph=true- Live graph chartcounter=0/1/2- Select counter (0=likes, 1=views, 2=comments)
URL
Click to copy the embed URL to your clipboard

